208 related articles for article (PubMed ID: 20832153)
1. Dense deposit disease associated with monoclonal gammopathy of undetermined significance.
Sethi S; Sukov WR; Zhang Y; Fervenza FC; Lager DJ; Miller DV; Cornell LD; Krishnan SG; Smith RJ
Am J Kidney Dis; 2010 Nov; 56(5):977-82. PubMed ID: 20832153
[TBL] [Abstract][Full Text] [Related]
2. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
[TBL] [Abstract][Full Text] [Related]
3. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
4. Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure.
Ali A; Schlanger L; Nasr SH; Sethi S; Gorbatkin SM
Am J Kidney Dis; 2016 Mar; 67(3):479-82. PubMed ID: 26704376
[TBL] [Abstract][Full Text] [Related]
5. Favorable effect of bortezomib in dense deposit disease associated with monoclonal gammopathy: a case report.
Hirashio S; Satoh A; Arima T; Mandai K; Awaya T; Oshima K; Hara S; Masaki T
BMC Nephrol; 2018 May; 19(1):108. PubMed ID: 29724182
[TBL] [Abstract][Full Text] [Related]
6. Causes of alternative pathway dysregulation in dense deposit disease.
Zhang Y; Meyer NC; Wang K; Nishimura C; Frees K; Jones M; Katz LM; Sethi S; Smith RJ
Clin J Am Soc Nephrol; 2012 Feb; 7(2):265-74. PubMed ID: 22223606
[TBL] [Abstract][Full Text] [Related]
7. Childhood-onset dense deposit disease: a rare cause of proteinuria.
Taranta-Janusz K; Wasilewska A; Szynaka B
Ir J Med Sci; 2014 Sep; 183(3):455-9. PubMed ID: 24338037
[TBL] [Abstract][Full Text] [Related]
8. Anti-factor B autoantibody in dense deposit disease.
Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis.
Li LL; Li ZY; Wang SX; Yu XJ; Tan Y; Wang Y; Yu F; Zhao MH
BMC Nephrol; 2019 Dec; 20(1):459. PubMed ID: 31823738
[TBL] [Abstract][Full Text] [Related]
10. Dense deposit disease in a child with febrile sore throat.
Conti G; De Vivo D; Vitale A; Fede C; Santoro D
Saudi J Kidney Dis Transpl; 2017; 28(4):925-928. PubMed ID: 28748900
[TBL] [Abstract][Full Text] [Related]
11. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
[TBL] [Abstract][Full Text] [Related]
12. C3 glomerulonephritis associated with monoclonal gammopathy: a case series.
Zand L; Kattah A; Fervenza FC; Smith RJ; Nasr SH; Zhang Y; Vrana JA; Leung N; Cornell LD; Sethi S
Am J Kidney Dis; 2013 Sep; 62(3):506-14. PubMed ID: 23623956
[TBL] [Abstract][Full Text] [Related]
13. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?
Bridoux F; Desport E; Frémeaux-Bacchi V; Chong CF; Gombert JM; Lacombe C; Quellard N; Touchard G
Clin J Am Soc Nephrol; 2011 Sep; 6(9):2165-74. PubMed ID: 21784830
[TBL] [Abstract][Full Text] [Related]
14. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.
Martínez-Barricarte R; Heurich M; Valdes-Cañedo F; Vazquez-Martul E; Torreira E; Montes T; Tortajada A; Pinto S; Lopez-Trascasa M; Morgan BP; Llorca O; Harris CL; Rodríguez de Córdoba S
J Clin Invest; 2010 Oct; 120(10):3702-12. PubMed ID: 20852386
[TBL] [Abstract][Full Text] [Related]
15. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
16. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Kidney Int; 2018 Jul; 94(1):178-186. PubMed ID: 29729982
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.
Ozkaya O; Nalcacioglu H; Tekcan D; Genc G; Meydan BC; Ozdemir BH; Baysal MK; Keceligil HT
Pediatr Nephrol; 2014 Jul; 29(7):1283-7. PubMed ID: 24464478
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal gammopathy-associated proliferative glomerulonephritis.
Sethi S; Rajkumar SV
Mayo Clin Proc; 2013 Nov; 88(11):1284-93. PubMed ID: 24182705
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
